subnormal responses found in patients given interriittent COT ticosteroid therapy by Malone et al. (1970). This finding, together with the satisfactory clinical response in these patients with severe disease, suggests that a therapeutic trial of depot tetracosactrin in a dose of 0-5 mg twice weekly should be considered for the control of disease requiring steroid therapy over a prolonged period. The effect of other dosage schedules on hypothalamic-pituitary-adrenal functon remains to be investigated. If these findings are confirmed in a larger series they may explain the clinical impression that it is easier to stop corticotrophin therapy than oral steroids and may therefore justify the use of depot tetracosactrin therapy in the treatment of exacerbations of chronic diseases. The ventilatory response to all three doses and by both routes was satisfactory. The maximal increase in FEV, after 5 mg orally was only slightly less than that after 10 mg. The maximal increase in heart rate after Smg orally was about half that which occurred after 10 mg. It is concluded that S mg orally and 0.25 mg subcutaneously are suitable doses.
Summary
Terbutaline, a new bronchodilator acting on f3-adrenergic receptors, was given to 10 asthmatic patients, who received on separate days 5 mg orally, 10 mg orally, and 0-25 mg subcutaneously. The ventilatory response was assessed by measurement of the FEV1 before and at intervals after administration. The cardiovascular response was assessed by measurement of the heart rate and blood pressure and by electrocardiography at the same times as spirometry was performed.
The ventilatory response to all three doses and by both routes was satisfactory. The maximal increase in FEV, after 5 mg orally was only slightly less than that after 10 mg. The maximal increase in heart rate after Smg orally was about half that which occurred after 10 mg. It is concluded that S mg orally and 0.25 mg subcutaneously are suitable doses.
In general a modest fall in blood pressure affected the diastolic more than the systolic. On E.C.G. the T wave was often depressed, and in one patient, it was inverted. A crough-like depression of the QRS baseline occurred several times. The significance of the E.C.G. changes is uncertain.
Introduction
In the search for a bronchodilator drug with optimal adrenergic activity on /3-receptors, Bergman et al. (1969) studied sevKing's College Hospital, London S.E.S BERNARD J. FREEDMAN, F.R.C.P., Consultant Physician eral compounds for their balance of P1i and /2 activity (Lands et al., 1966 (Lands et al., , 1967 (1970a) found that equal subcutaneous doses of terbutaline and orciprenaline caused similar maximal increases in heart rate which appeared to persist slightly longer after terbutaline. Orally terbutaline 5 mg and orciprenaline 20 mg caused equal increases in heart rate but orciprenaline caused a greater stroke volume. Carlstrom and Westling (1970) confirmed a preferential action on 12-receptors. A bronchodilator response in asthmatics was observed after terbutaline was given subcutaneously (Arner et al., 1970b) and orally (Mattila and Muittari, 1969; Arner, 1970; Formgren, 1971) .
The following is an account of the ventilatory and cardiovascular response to terbutaline in 10 asthmatic patients.
Materials and Methods
The patients were selected for their known responsiveness to bronchodilator drugs and for the small spontaneous variation in the degree of their bronchospasm over comparatively long periods. At the time of testing they were in remission from acute exacerbation. Their clinical characteristics are shown in Table I BRITISH MEDICAL JOURNAL 20 MARCH 1971 rument gave ill-defined readings, and in these the conventional auscultatory method was used. Electrocardiograms were obtained before treatment and, using standard lead II, repeated afterwards at the same time intervals as for spirometry. When certain abnormalities appeared 12-lead E.C.G.s were obtained for comparison with the 12 pretreatment leads.
Tests for toxicity were made before treatment; after the third treatment when given on consecutive days, or after 10 mg orally when given at weekly intervals; and about three weeks after the third treatment.
Patients were asked not to take bronchodilator drugs during the six hours before each experiment unless in need, but the need did not arise and no postponements were necessary on that account. Steps were also taken to ensure anticholinergic drugs were avoided. increases in FEV1 for each patient are shown in Table III . These values are slightly greater than those shown in Fig. 2 because the individual patient's maxima occurred at different times after administration. The maximal increases in FEV1 after 5 and 10 mg orally differed significantly at the 5% level, but not at the 1% level.
A measure of the overall activity is the integrated increase, corresponding approximately to the area under the response curve. There was no significant difference at the 5 % level between the integrated increases after 5 and 10 mg orally (Table III) .
635
Blood Pressure.-The mean changes in systolic and diastolic blood pressures were small (Fig. 4) . Apart from small initial rises in systolic pressure with 5 mg orally and 0.25 mg subcutaneously, the general trend was a modest fall which affected the diastolic more than the systolic and was dose-related. The untreated-hypertensive patient (Case 3) sustained greater falls than the other patients, but these falls were all within the therapeutic range. The B.P. of the other hypertensive patient (Case 8), who was being treated with methyldopa and polythiazide, underwent modest rises. In no instance was there a rise or fall in blood pressure to cause the slightest concern.
ELECTROCARDIOGRAPHIC CHANGES Reduced amplitude (depression) of the T wave often occurred; the incidence was as follows: 5 mg orally, five patients; 10 mg orally, eight patients; 0-25 mg subcutaneously, eight patients. The onset and duration of T wave depression corresponded generally with the onset and duration of ventilatory and heart rate changes, but individually there was little correspondence. Thus some patients with T depression had no tachycardia, and vice versa. The degree of depression amounted to flattening in seven instances. T-wave inversion occurred only in one patient (Case 9), who had diabetes and treated hypertension, and it occurred with all three drug presentations.
A trough-like depression of the QRS baseline was observed several times. This is not seen in ischaemic heart disease, and its possible significance is discussed later. Depression of the ST interval did not occur, except as part of the above-mentioned phenomenon. No arrhythmias occurred after administration of the drug. On the contrary, one patient (Case 10) had atrial ectopics, one in six beats, before administration, which ceased with the tachycardia.
CARDIOVASCULAR CHANGES Heart Rate.-The mean changes in heart rate are shown in Fig. 3 . Patients differed markedly in responsiveness. Thus the heart rate of Case 1 fell initially, that of Case 4 remained almost without change, while Case 9 was highly responsive and achieved larger increases with all three drug presentations than the other patients. The times of maximal change in heart rate were about the same as those for maximal ventilatory increase. The means of the individual maximal increases in heart rate were 18-8 after 5 mg and 34.6 after 10 mg orally; after 0-25 mg subcutaneously it was 12-5. (Mattila and Muittari, 1969; Formgren, 1971; Fagerberg and Tegner, personal communication; Bernstein et al. 1971) . These authors report rises in heart rate of only 0 to 6 per minute after 5 mg orally and of 5 to 9-3 per minute after 10 mg. The greater tachycardia in the present series may have been due in part to the mode of administration, which favoured rapid absorption-namely, fragmentation of the tablets and ingestion with a relatively large volume of water on a probably empty stomach. But this could not account for the tachycardia continuing, and, furthermore, after subcutaneous injection of 0-25 mg the increase was 12-5 per minute whereas Amer (1970) obtained an increase of 3 to 4. It seems the patients in the present series may have been unduly sensitive to the cardiovascular action of the drug. Little has been published about E.C.G. changes after administration of drugs with predominantly /3-adrenergic activity, Littman et al. (1950-1) described a trough-like depression of the QRS baseline after 0.25 mg of isoprenaline given subcutaneously, which was similar to that observed in our cases. They suggested that it was due to augmentation of the atrial T wave. This phenomenon is not characteristic of myocardial ischaemia, and it may be a specific response to ,Badrenergic activity. Its clinical significance is obscure and it is currently the subject of further study. Riding et al. (1970) described depression of the ST segment and depression or inversion of the T wave after inhalation of isoprenaline aerosols. There were no instances of ST depression after terbutaline, except as part of the trough-like depression of the QRS baseline previously referred to. Some degree of T-wave depression occurred with many of the patients, and inversion occurred with one patient. The significance of this is not clear, and it would be premature to ascribe it to ischaemia in the present state of knowledge of E.C.G. changes after administration of /-adrenergic drugs. In my experience T-wave depression is common after administration of sympathomimetic bronchodilators. 
